At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 54 enrolled
Drug / intervention
MK-8777 +1 moredrug
Likely dose
MK-8777 50 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Single Center, Randomized, Placebo-Controlled Trial to Establish Maximum Tolerated Dose, Optimal Titration Schedule, Safety, Tolerability, and Pharmacokinetics of Org 26576 in Patients Diagnosed With Major Depressive Disorder (Protocol No. P174001)
In Brief
A Phase 2 clinical trial evaluating MK-8777 and Placebo for Depression. Completed, enrolled 54 participants.
Detailed Summary
Trial to determine the maximum tolerated dose (MTD) based on safety and tolerability of MK-8777 (Org 26576, SCH 900777) in participants with major depressive disorder.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDepression
Countries--
Collaborators--
Timeline
Phase 2CompletedFinished
20082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartSep 2007
First PostedFeb 2008
Primary CompletionNov 2008
Study CompletionDec 2008
TodayJul 2026
First PostedFeb 8, 2008
Enrollment StartSep 20, 2007
Primary CompletionNov 18, 2008
Study CompletionDec 10, 2008
TodayJul 2, 2026
Enrollment to primary: 1.2 yearsPosted 18.4 years ago
Interventions
MK-8777drug
Orally administered capsules containing either 50 mg or 100 mg MK-8777.
Placebodrug
Orally administered matching placebo capsules.